<SEC-DOCUMENT>0001193125-16-756153.txt : 20161102
<SEC-HEADER>0001193125-16-756153.hdr.sgml : 20161102
<ACCEPTANCE-DATETIME>20161102070608
ACCESSION NUMBER:		0001193125-16-756153
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161102
FILED AS OF DATE:		20161102
DATE AS OF CHANGE:		20161102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		161966275

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d284326d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 5, 20 George Street, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 2 November 2016 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">483 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deputy Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr James Garner</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Managing Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 November 2016</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVOGEN&#146;S DR JAMES GARNER DISCUSSES IN-LICENSING OF GDC-0084 WITH
FINANCE NEWS NETWORK</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, 2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> November 2016 &#150; Australian oncology-focused biotechnology company Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to invite investors to view a video interview with CEO, Dr&nbsp;James
Garner, where he discusses key elements of their in-licensing of a phase II ready molecule <FONT STYLE="white-space:nowrap">(GDC-0084)</FONT> from Genentech for treatment of brain cancer (Glioblastoma).</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To view the video interview, please copy and paste the URL below into your web
browser:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>http://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN813</U></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interview transcript</B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-Begins-</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert: </B>Hello I&#146;m Carolyn Herbert from the Finance News
Network (FNN) and joining me from Novogen Limited (ASX: NRT; NASDAQ; NVGN) to discuss its licensing deal with Genentech is CEO Dr James Garner.<B> </B>James, welcome to FNN.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner:</B> Thank you Carolyn, it&#146;s great to be here.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert: </B>Can you start by giving us a brief introduction to Novogen?</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>James Garner: </B>Novogen is an oncology focused biotechnology company; we&#146;re targeting new therapies for a range of different types of cancer. We are
listed on the ASX, and we are also actually listed on Nasdaq; we have the advantage of being present in both countries and we have about 40 per cent of our shareholders in the United States through Nasdaq. We are a lean team with about 16 people,
from a variety of backgrounds including a number of people from a background in international pharma. We are a well capitalised company, we have about a little north of A$30 million on the balance sheet and we have now after today&#146;s news a
pipeline of four molecules of which two are in clinical development and two of which are still in animal studies.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg03b.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert: </B>Now to your deal with Genentech, can you tell us a little bit more about that? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner: </B>We have successfully in-licensed a new molecule from Genentech and Genentech by way of background is one of the world&#146;s most
successful oncology drug development companies. It&#146;s the company behind drugs like Avastin and Herceptin which have been very, very successful in their fields; it is part of the Roche Group which is the world&#146;s third largest pharmaceutical
company. The molecule we have in-licensed is part of a class of drugs called PI3K inhibitors and these drugs target a particular process in cancer cells and it has been an area of interest to pharmaceutical companies in a range of different cancer
types. We are developing the drug in an area called glioblastoma primary brain cancer which is one of the most challenging indications in drug development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert:</B> So how common is glioblastoma and what are the current treatment options? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner:</B> Glioblastoma is one of the most common forms of brain cancer and there are about 12,500 new cases each year in the United States and
perhaps about ten times that many worldwide. It is a very challenging disease to treat. Life expectancy at the time of diagnosis even with the best available treatment is something like 12 to 15 months. After five years only about 3 per cent of
glioblastoma patients are still alive compared to somewhere like 89 to 90 per cent of breast cancer patients, so it remains a very challenging disease to treat. The most commonly used pharmaceutical treatment at the moment is a drug called
Temozolomide, otherwise known as Temodar, and this drug has been shown to be effective, but it&#146;s only really effective in under half of the patients with glioblastoma, so there is still a very real need for new therapies in this disease area.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert:</B> James as you say other companies have been looking at this disease area, so what makes your drug different? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner:</B> We are excited for a number of reasons; the first is we know the PI3K pathway is very relevant to glioblastoma as a disease area.
Somewhere around 80 to 90 per cent of glioblastoma patients have a disordered PI3K pathway as part of their tumour. So this represents a really good target for drug development. The second advantage of this molecule is that it is able to cross the
so-called blood brain barrier, which separates the brain from the circulation, and is often a challenge for new drugs that target diseases of the central nervous system, so this is something that really differentiates it from most drugs in the PI3K
class and indeed most other drugs that have been tried to approach glioblastoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert:</B> So what does this mean for Novogen, and does the
company still plan to develop its existing pipeline? </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner:</B> Yes we do. We have a pipeline of three other molecules, apart from the molecule
we just in-licensed and the most advanced of these is about to enter human trials for the fourth quarter of this year with ovarian cancer as a lead indication. So we continue to work on the rest of the pipeline and we&#146;re looking forward to
seeing those molecules progress in parallel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert:</B> So James, can you tell us some more about the deal terms and how do you know
it&#146;s good value? </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner:</B> We have paid US$5 million for the molecule as an upfront payment and we also have some limited commercial and
regulatory millstones as the project moves forward and then a royalty payable on sales. So we have benchmarked the transaction quite carefully against other comparable deals in the life-sciences space and we feel the transaction we&#146;ve done is a
good one for Novogen and it represents good value for the company. We have also had an independent fairness opinion prepared by an independent corporate advisory firm in London and they have confirmed our view that this represents good value for
shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg04.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert:</B> So what happens next, what are your plans for the drug and do you need to raise
further capital? </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner:</B> Our immediate plans are logistical, we have to transfer all of the data and all of the regularity matters from
Genentech to Novogen and that&#146;s work that will probably take the next couple of months. One of the key things is to transfer the open IND, with the United States Food and Drug Administration from Genentech to Novogen. We also get as part of the
deal a large quantity of pre-manufactured drug substance which will be a great help for us when we are starting the clinical trials. So the logistics of transferring that to our ownership will take us a little bit of time over the next month or so.
In parallel to that we are going to be investing plenty of time in planning the optimal phase II clinical study. We will be sitting down with key option leaders, as well as scientists and clinicians to work out the best way to take the drug forward
and that&#146;s work that we also anticipate will take place over the next few months. In terms of our capital requirements we remain a well funded company and we will obviously be continuing to evaluate our portfolio in light of the work we are
doing and keeping a close tab on that. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carolyn Herbert:</B> James Garner congratulations on the news and thanks for the update. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James Garner:</B> Thanks very much Carolyn. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-Ends- </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Media and Investor Relations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Investor Relations (US)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glen Zurcher</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E:
<U>glen.zurcher@irdepartment.com.au</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">T: +61 420 249 299</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Kennedy</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E:
<U>robert.kennedy@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">T: +1 212 519 9832 / +1 646 662 3574</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the GDC-0084 development candidate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GDC-0084 is a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is distinguished from other molecules in the class by its ability to penetrate
the blood-brain barrier. The molecule was developed by Genentech, who completed a phase&nbsp;I study in recurrent glioblastoma patients, and was licensed to Novogen in October 2016. A phase II clinical trial is slated to begin in 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Limited (ASX: NRT; NASDAQ:
NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of four development candidates, diversified across three distinct technologies, with the potential to yield first-in-class and
best-in-class agents across a range of oncology indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg04.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being
developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase&nbsp;II clinical trials in 2017. Three further molecules have been developed in-house from two proprietary drug discovery
platforms (superbenzopyrans and anti-tropomyosins) to treat ovarian cancer and a range of solid tumours. Cantrixil, the most advanced of these, is slated to enter clinical trials in late 2016, while Anisina and Trilexium are in preclinical
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit: <U>www.novogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g284326tx_pg04.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g284326tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284326tx_pg03a.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
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MXQ]!M^#O6+F4A)\E[J?2_0R^JQR7% * 4 H!0"@% 759/U-S\\O\EJ@):@%
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MJD'5.O D<0=.H\* N*@% 5'0?-\(H >D^<^_0%* 4 H!0"@% * 4 H!0"@%
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M(GXE^3E+TL\%>BTM#R3OU20>QL_!50RRSTGSFJ I0"@% * 4 H!0"@% * 4
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M#J>;#K3C9Z%H4G[X.A^_50RR'6UM.*0L:*2H@CS=?F(H$==4 H!0"@% * 4
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M\Y+R?YLP\/!O9-EO%G9=RD[T.\[,_$E+6<%)VZ4;E%QUYE3[;US<^S!0"@%
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MXR4]QW#+X5J2X1P-= 8G\,3_ (O-VMK-B-[LOW_VY]A;BX9@VX>1X+:_#HQ
M>]G9#;8=VN&-V_+CN*\[$<#3Y9;G&&LI.B^Z/R:JZ)Z QYM)XN]U9OC"W,V?
MW88Q1K9K(MW-SMF?#_DEGM:[;=;9N/M-9\<RNYX)FT]<MYBYW',\/R-R;:7.
M1I3B[:\V 2:-)+U V.P7=3*LL\1?B>VNNQMAQ;: ;(JP[U6#W%R W"P&5D>0
M^UIW?+]H:W..GN/01W3?H^ETU2FE09\J@% * 4!XG/EJ\] <* 4!B6Y_M&?_
M &R1^E569'V5V&LW_P 3/M?TGAKT>10$7??V)=?[!*_1&KMGVO68N;^#N_RY
M?0S7NI4T04 H!0"@% * 4 H!0"@% * 4 H!0&)MYP/W.;_QJ!^BEGWZS]N_$
M/]EFK^;DGM<:_P#S1^B1;>VOB*S; O5[=/=5E6--\J#;+F^LS83(X$6NZJ[Q
M]D)3T-N=XUPX!-7,S:<?*K.'<O=:Z>U$;Y=\_P"\[&HX^0_>MN7V)OO17^B?
M1V2JCZ9;+9[C^[-CN-XQI4UIBW3H\.YL7*,8\B',>BB2F.DA2V96C2M>=M11
M]WA6HYV'>PKJMW::K2G2OJ/H'RQYAV_S%B3RL#Q$H349J4:.,G'FI6K3[5Q,
M]1XC,8?1IU7UN*T*_N'YH\U81LQZ: 4 H!0%1T'S?"* 'I/G/OT!2@% * 4
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M*'8?@/2* C'X"AZ3*N8:?5J^4/Q2>!H"-*5 D$$$=((XB@*4!XG/EJ\] <*
M4!B6Y_M&?_;)'Z4UF13Y5V&LW_Q,WT5?TEF7G*K99PMOG$R8G@(D=0)2K3H?
M=XH: /3TJ\E9%NQ*X^J/6167NEC%3BN_>ZE^DQ5=\DNEY*DR'>YBZ^C#8)2R
M!U=X?E/*!ZU:CR5GPLPAP7>ZS6,G.R<O2<G&W^JN'^9 U=,04 H!0"@% * 4
M H!0"@% * 4 H!0"@,3[S_P<W_C4#]%+K/V[\1_M9J_F[^UQ_G1^B1JU4R<S
M/J)X!_X'W _U?;_\B16I>8OO[?['_<=_^#G]JS?^3#]Q&^-:X=B% * 4 H"H
MZ#YOA% #TGSGWZ I0"@% * 4 H#YR>+G_N5:O](6[_,KM6R[-^%?\Q_0CB'Q
M)_OUO_BP_>F:LU+'/A0"@.#GU;OYIS\A557$\R]E]AK$RR_*>;CQ679$AY00
MTPPVMYYQ9X!*&D K63Y*E'1:R=(FJ*$KEQ1@FY2>E.DV#VZV:N3UXLESR9Y5
ML99NMMDM6R.4N7!Q34UAQ E.CF:B(U2-4CF<\U1F5GPC"4+2JZ/7H-TV/RK?
M>3:R-P?AQ5R+Y5K*O,N/4NOI]1]2FXT>/S(89:;3J?DI&JN/2I7%1)\IK4Y3
ME)^@[["S;M1Y;:27^.LX/Q8\E)0^RVXDC3BD<P\J5#TDGS&J*Y-<&)V;=Q<L
MTFBUYV/NM@N0E=Z@?^BK@ZGR)5T.#[Q\]9,+Z:[W$B+^W3A65C6"Z'Q79UEN
MJ"D$I6"E2?E)4"%#S@@$5?JGPX$<TTZ/B*%!0"@% * \DF&Q)'IHT6!Z+B>"
M_(-3J%#SU4HRW)=L?CZK [UO7Y2 20./RD<2//T4*D;5 * 4 H!H3515'LC0
M7Y1]!!".MQ1Y4_<U'I'S4!<<6VL1M%$!UP:>FH#@>OE3Q \G70IK4D:H5% ;
M1[9?P;;?S]Q_OKM1&7]^^Q?0;_L7]KAVR_>9?U8Q+"@% <TK6D:)44@\3H2-
M?/U'IH5JZ4Z"BEK6-%*) .NA/#7S=%"GH.- * 4 H!0"@% * 4 H!0"@% *
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M&YEIP5NSS,;SK(VK1!NV8Y?CS=P3AV-M)SJZ7=J!C;;B[>VA+Z'G7$J2 V0
M-P<=>NDJP623?3$%YE6FWR;IZA;[I:H7KLB,T\^(UKO:EWFVM!3G!B63(:^0
MYZ0- 8%V<W=R_<K=C>?$;C"L=NQ;;/.\BP>UB'B>?,76>NR2;(RQ=I.;W1*=
MO[LN4BX/%ZWV\JEQ2$%S0!6H$1MCX@;[GCWAD1/QRT0&]^-L=T,]O*X4F<[[
M!EX!(Q-F)!M!>)3*ASSD:@\MX\R%-I">)(H"=VHS7>7)MW]T\$S=6U"<:VSF
M8G;U2\0MF9QL@N[N<8S'RBSOI5?+O-ML1JV1W3'E)*%*><3SME"?1JO0"'VW
MW^O><)\.:IF/6> -[8.]TNZ&-)FK%G5M1,]4@HM)=41)%R.GK/>ZEM7!-* L
MO:;Q.9=N%XA\LV>E6+&'++8KOO/!>>M-LS6UW_&+5M;EMJQ2QWZ\W?(&$X?F
M47-)UQ4PMJQN*=M<E*4R $DD*,&0=D]W,YW0S;=N!=[59K5B6 YYG>#V80\/
MW!A39[F(Y9(QV-<7,[O/+@>1.3&8;CDB):P7H;BDI<TY5:F"\=W]P\CPV1ME
MBN%V['IF:;N9XY@N.3LPE7"-B5B7 Q7(<TN]UO"+2/:EUDILN-/M0+=&6R[/
MFN(1WK:$K6* Q)>?$-FV,;.>)K)+[CF)R-S/#5<+A8[HS8G;],P'*Y_[M8OE
M]CN-O95S9/!#UERQA$^U%;TV)-:6TAQT+;60-A=M+[?<EPJSWW)%V]=VN!FN
M/&VXMF&$Q>Y:G2&(P_=?/@G++4\&6ASIEI25*]- Y%)H"^Z 4 H!0"@'10%O
M264..NG3E5SKXI _G'I'0>% >=,9(.JCS=@Z!Y->/&@/4D %(   (T X <>R
M@-"LR_B_*/\ 'KG_ 'MVMCL?<P_91Q_<O[ED?SI_O,MNKIA"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0&)]Y_P"#F_\ &H'Z*76?MWXC_:S5_-W]KC_.C]$C
M5JIDYF?43P#_ ,#[@_ZOMWNV) 'WS6I>8_O[?['_ ''T!\'$_P"DYKZ/>8?N
M(WQK7#L(H!0"@% 5'0?-\(H >D^<^_0%* 4 H!0"@% ?.?Q>-N(W&LSJD*#3
MN(PDM.%)"'%,W*YAU"%="E-]XGF Z-1VULFS->[275-_.E^@XC\28R6^VI-/
ME>+&GJE*OTFJO14N<]+DL6*WB_J!B,=U%YM%SY.K<9('RN0Z<[ZAV(!X])%6
MKEZ%M=;]!(86V9><U*U&EJOM/A3T=9FRP819[&$/*0+A/ U];DH!2VOA^K1^
M+;0!Z">97E%8%V_.XJ<(]1N6#LF-A4F^_?72^'J707@LDI42?FJ]XU8)BB2=
M.HQE\9]\U?CP(A<#VVL%=UMJ$@J6JX0@E(&I4?6&SP XG@#5)^P^PNV*N_;2
MX\\?I1MHKY2O.:ASH+T>IQH4% * J#I2K7 =-2)FV>+,U4D".^3KWK:0$J/_
M #$:<J@>T:'RU=A>E%ZZHP[^%:O.J[MSKZ/6BT9ENE03J\V5-Z\'VP5-'K&J
MNE)TZCI65&Y&7#B0M['NV'WUW>M<#P5[+!6@% * 4!Q*4D$%((/ @@$'S@\#
M04/,8$,GF,=K7\7X.CKJHHCT(0AM/*VE*$_S4@)'WATT%$<ZH!0"@% * V,P
M[(<>QC;^VW/)L@L6-6TS+@P+CD-XMUD@J>,QY093+N<F*PITIXA(5S:<=-*C
M+]J[>R7;LQE.=$Z)-OYD;IM^X;?MNRPR-RR+&/C\[7/=N1MQKS/3FFXJOHK4
MR;$EP[A%CSK?,B7"#+:0_$G0)+,R%+8<&K;\:5&6['D,K'$*0HI/;6'*,H-Q
MFG&2>J:H_D)VS>M9%N-['G"Y9FJQE&2E&2ZTTVFO2M#RQ;S99UPN-I@WFT3;
MM:.Z%WM<.YPI5SM7?CF8%SM[#[DNWE\<4=\A',.C6O4K=R,%<E&2A+@VFD^Q
MM4?J9:M9F'?O7,:S>M3R;5.>$9QE.%>'/!-RA7HYDJ] E7FS0)UNMD^\6F!<
M[PMQNSVV;<H42X79QD)+S=KA2'VY-Q<:"@5)92LI!XTC;N2BYQC)PCQ:3:7:
M^"[71%;N9B6+UO&O7;4,F\VK<)3BIW&N*A%M2FUT\J="&NL+"<^A7G$[N,>R
MR%"G6HY!CRY<2XFWW*U7*'?[,F\08TA4B!,AW2VL2F4/!"N=E*M"!5'"<8J4
MHM1DJIM4376GTJO2A:R\7(NW+&/=M7+UJ5)QC.,G!\:32=8.FM)4=$>?*;AM
MW:K]B5]S6\8=9LDL\NZ.X3<,GOEHLURB2[Y#]DW==B]I3HBWW+E"/J[O=I7S
M)]'IJY;L9%Y-V;=R:2UY8MT[:)EC-W7:ML<%N65CX\KGL*[<A;<]:=U3:<JO
MA0M[)=KMGY6 Q</R?&<9B[<8[<V<HA0)4YZQ62PW=JZ3+RS?HUUC7*W/6N4B
M[7=]\/ID(^DD*XZ*TJW",YR4+:<KCT22JWZ*<:^@RK^1CXUF61DW+=O'@JN<
MI*,$NMRDU%+TMT+CPRZ8"Y;(V/8%D&,W:W8[!C16K?8,GA9([;(""6HHE.M7
M.YSPA124I<D+4I9!](FO=RQ?LT=Z$X)\.:+5>RJ,7#W7:]Q;CMV3CY$HI-^%
M<A<HGHF^23HFTZ-Z/H/+:;KMEB]XN^/V:_8/8\@ON3S[_>[#'R.RQ;W<<OO:
M8KD^XS+0NX>T%7FYH89*AW86L!.B>BJK'R7;\96[CM4KS<KI3A6M*4/,MXV>
M&5[C/+Q5G<W+X;O6U<YN/+X;ESUI2BY:NJI4B\/V5VGV^R.\Y;A6!6'&LCOJ
M)[-QN=N:E!:8]TN1O-VAVN)(E/P,?@7:\?UN7'M[45F3) <=0I8!%DD2:F3-
MN<&O=VO=RNN'8?D&:JMLN\W"[WNU6&X9*K'(*+-:Y+RKG.C+F^R+=RQT*0-&
MT: \:NV[%^\F[4)RBN-(MT[:)F#F;IM>W2C#<,G&QYRKRJ[=A;<J<:*<HMTZ
M:%E[>[=;!6[*;_N!M=9< =RFY.7!N]7W$;M'O1B.Y%-%XO346+#NEPM6,KR6
MXLB5-1"9B>T'T!QX.*3J%RU>M4C>A*%>',FODJCUA;CMVXQE+;LBQD1BTI.U
M<A<46^"ER2E1OHKQZ"7AVC9>WJC9[;QM[$1C-^S6XL9C&N]I;AV7(]P)+'[_
M !>O@N'J4:9E%P0R;@PZYH[(2V2@+2C1X%_Q%9Y)^(]4J.K[%2IX_JNU>[2S
M?>L;W*$N65SQ8>'&2TI*?-RIU:5&TZM+B+5M[M'MS=LDW(MELL.(3LEDS[MD
MV3/7^;;[-/F9)<&9UQNDIJXWG]VHLF]7(MN+?;9:6\XK@HE1U\PA<N2Y+<7*
M?4DV]..G'34R+^7B8UAY63=MV\5)-SG)0@DZ)-RDU%)MI*K56U2M3V7JV[3[
MV8_.Q>[+PO<K'FI5OFS($&\V^])MESAO*E6>YL3;'<#.L=XAOMER)*8>8DMJ
M!+:QQKU<LWK%/&A*%>',FJ]E46</<MMW%2>W9&/D<GM>%<A<Y:\.;DE*E=:5
MXT="WK3B_A_MF-S]CK.SMHSC]S?N4.\;;MWZTR9EWN%PDB;>1?+>_='L@N][
MGS4!V4[*4[+=<&JU'2JO'R.3Q?#N>$U7FY72G76E"VMWVB65[C'+Q7G)T\)7
MK;N<RXQY.;FYETJE49G==T#CS[@2E*5NNNNK"4H0A)6MQUQ9"4(0@$E2B  *
ML\73I9(2<81<I-*,4VV^"2XMOH7IX$?:[O:+[":N=BNUKOEM?4XEFY6:XP[K
M;WE-**'4M38#TB*XII8*5!*R4J&AT->YV[EJ7)=C*,^IJC^1EG&RL7-LK(P[
MMN]CRX3MSC.+HZ-*46XNCT='H1<C,\,AW86"9F6(P[\768_L*7DUDBWKUB2E
M"XS'LI^<W/[^2AQ);1W?,L*! .HKVL?(E;\6-N;M?K<KI\M*&+<WC9[.5[C>
MS,6&;5+PY7;:N5=*+D<N:KJJ*E7543)&Z7NR6/U/VW>K19?:,M$"W^V+I!M8
MGSU_(@PC.D1Q+FKZFF^9P]0KQ"U<N5\.,I4571-T76Z5HO3P+^3FX6%R>^7K
M-GQ)J$/$G&'--\(QYFN:3_557Z"K=ZLKMWD8^U>;0[?XD9$V786[G"<O<2&X
M6PW+E6E#YGQXKA=3RN+;2A7,-#Q&KPKOAJ]RR\%NBE1\K?H? K',PY94L&-Z
MR\Z$>:5M3B[D5I1N"?,DZJC:2U6NJ)*O!DB@(-[ZUW\XO\HT!UT H#2G=&QR
M;)F5U4ZA7JMW?7=8+^GHNMRCSO("OY\>05)4.GH/6*GL.XKEB/6E1G*M_P 2
MYB;G<E)/P[LG.+ZZ\?D?'M,>UE$.* 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M 8GWG_@YO_&H'Z*76?MWXC_:S5_-W]KC_.C]$C5K4#B2 !Q)/0!UD^2IDYFV
MDJO@?8KP>8#/PG:5$^[,.Q+CFMS5DOJCZ5(>CVPQF8=H#K:@%(<D1FB]H0"$
MNIK2-\R(W\YP@TX05*^GBSZ<^&.S9&T^6E=R4XW\J?BM-4:A1*%5T-Q5>QFU
M=0QT44 H!0"@*CH/F^$4 /2?.??H"E * 4 H!0"@+/S/",2SJUFUY9:X]P82
M%JB/GF:N$%U8&KUNF-:/QW#RC4 E*M!S U>LY%VQ+FM2:?S/M(W<]HV_>+'N
M^X6U."K1\)1;Z8R6J?S/I3-0[GX98V.RY%RMCTK*K<AU3D6!*0VW-B-)X@/L
M,Z)N901\I/+P'%&M3$-V=U*$THSZ^O\ 0<[O?#ZW@W'D692R;*=5%T4DNII>
MWVJG817=]R SW?<AGZ,,\G=]SR\.3N]$]WR]F@TKU6KKQ])11C'N)<M.BE*>
MB@H>CBKY*OQ5>\:!\'V%M6'$+QD!#C#)BPB3K/E!2&"-3J&4\')"A^"-/**]
M2O0@J=)BXFW9.7[*<;?ZST7JZV9ML&&V?'^5YI!F3P.,^2 5H.FBO5VN+<<'
MM&JO+6#<OSN:/1&SXFV8V)227-=7VG]74775DD!0"@% * 4 ("@4J&J2-"#Q
M!'80>!HFTZAI-4? M^;8&7]5Q%>KN'4ELCF:5U\/G-DGLX>2LB%^FCU1&7MN
MA*LK/=EU=#_06J_%D1%]V^TML]1/%*OQ%]"QQK)34M4R(N6[EF7+<BTSHJIX
M% * 4 H!0"@% * 4 H#YO[D?]!KCX\6K1X\94%&Q+.Q%NE^'6)G\V[6_:)[*
MGKDV,\D7%V$['A.9$F9ZX@%Y8 *60OHCZ[IA?U.'EAS\L5>Y^]-7^2CN\M%R
MTKT4IP3K5TUJ?-7F5^2,CXYO$^-LHKR5'98RVI9,KD,%W7->\\SBU%W>;Q%6
M3T?(GPMH^I'AQS'PJ8/X9[AEWAVN<!/AVVY7N5>')L>3?7(,9>-S;E>\M]6F
M92KVF_"[Y*O5%J46E1E-!H\G+6E;MC[WE;S''W6+_JE[PU3N_:TCI'I?3TUK
M7@?2?P^W?X8;)\.+FZ^0+MO_ .@;>\N;DG<Y8NRYW+ZYK_?:JJ0;?+RN"CH?
M$WP0;MY;AGBTVMWXSW$-S\5M?CGNVZ&/YIE^96-RU[=Y+?LKR1W*MEDX#?'G
ME(NS=JML5F"[S(:Y>\U;YT$D='\R8%C)V"]MN+<LSGML;<H0@ZW%&,>2[SKT
MZR]/32A\;_!;S5NVT?%3;?.V]XFYXV-YTNYEK(OY%MPQ+MR_=\; ]VN-TFH)
M1M:J-.;N\R=3;3[5# \UW*\2?@/PW;/(!BNYTP[VW7;J^%89,7-L4MN.95CC
M"W2I/=,7&ZV5N*XHZI2E[50*=14%Y'R<?$VC<\C,CSX:\)37^B7-&6G31.OJ
M.H?F>V7=_,'Q$\D[7Y=O^[>9)+<+F+<K3EOV(VK]I5Z%*=M1;KTZU547!]E#
MN3==W]S_ !U[D9-CKN(Y/E6Z.V\K+\8?'+(L.4P<7N]HR:W.MJ"7&>XOEOD<
MB%CF0DA)X@U9\]8EO;\/;<.S-7+,+$^62X2BYQDG\C521_*YYBR_-?F+SKYA
MW+'>+N61N.)*]9?&W>C;NPO0Z'I=C.BZ%H]:FO%O:\'=[\37CF1]I7,LK>Y5
MNW DQ]L8^Y]TR6VVF#L:F!(_=ES:9-KD,(]?<B]RMHQ>:0LJ0IH%9?UEI_UZ
MSM&VOR@I>Y.TO$<%%MWJZN[5-T74^IFA8L/A/G_$3SI#\PT[2\QV\^4<19=R
M_""V[EEX/N?(TG-JC2@W)Z.*<N<^@GBYF[?3_LN]V9NU3@>VO>\.EI_<%PB<
M%JQ)M>/LV7O?:VER]93#;2'#(^F+H//Z6M:IL,<J'G2Q'.TS5E/G6GMTE7AI
M2OZNG4=X^*MW8LG\M>YW?*[3\MRV&W[J^]]PG:5NO/WZ\J55/O5TEK4Q#]E%
M#VNA8GDQQQ'A08SZ9AFW;MV:\.M]R2ZY>]C3=NU<?WCBW^4^Q!R=.0/$.)AI
M0P)2G0.'**D?//OKO0\7W[W57)I>\1C&/-73PJ)5CR\&]:&J?E=M>6[6UY+P
M%Y86^3P\1S6U7;T[SLJ%6\^-R3C"]XKHU;I%2YEU(^5'C8QE=S\2'V@V0';;
M&[G:+'N_L#;;[OW*N5V3E7AR9O\ $M#3.5V&P69]B1=H-Y]45'FNJ)3&Y&@
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M/?:6E ^S)W**O11^XFS'\T:#][< Y0.;1.IZJYYY-T\Y6F^/BWG_ -,SZ_\
MS&-/\M^X=7N>W?\ ]L9'#[,&'M;!V_S1K#4>%1C,)#^'OY4QX7;YD=YBKLJ+
M&48_(W%3DDJ1(AY;[27<4K2P$Q]><)U(X4\Z2S9Y5IY'OSL]_E]XC%=[FK+P
MW%*L*<M$ZOAJ5_+9;\N6=BS([3_]96[.5AW5L]V[<7AJV_">2KK;A?<W=K&-
M(]5>CXH;\8MZYOAXL<IF85C./X[%\?\ B>-7GQ5KNUT.8;#.7&\/34,Q\>M$
MAE;N.WIF*M;LUWT&I* V"'%(*>C;9?2VS"L*[*=][7*2QJ+EO427M/[2;]E:
MM:\#XV\\;9*[YR\R[G>PL?'V^/GBS:GO/B2\?;N:Y*55:@ZNU/E=;CTC)4]I
MIK[]?:.;Q2]I/"#GJ\5ENW'.=V&+1LOMJFVK$JZ7S(=RM+.9-G;BE:Y\TX\J
M9(:#/-S.%&G!0KEOE#;X[AY@M1OKEQ[#=VY71)6W5)UX=])/IT9]V?F$\V7?
M*WPHSOZ9-W-ZW10P,3D=9W+F7W'*VH^U+PN>4:53;CUHU2^RFR16VN3;]^$.
MYXMN'M_'Q&5C^\&U^(;LV?\ =W.F\-RNUVZS98N5:#(E($5&5PD2&EM.+0IN
M5KP5S)$[YXL^^6<;?X3LW7<3M7)6FG#GBVXZJFO+IJEP.7?E>W&7E[<-\^%>
M5C9^!#%E:S\2SG0\+)\"]",+[E;J^ZKRC)--Z3JZ<%I_XE/#_G/B-\;?CRP/
M;+8W#MS<TDV[8EJT[F9+GL?"IFPDJ3BE@<&76IA2A(OSMT8AK9=::"E-):2K
ME5J$*V'9]UQMH\N;9DYN3.SCUO5MQ@YJ\E)]VO!4JG5]AR/X@^1=\^(/QF\[
M[+Y:V7%W+=W';5#+NY*QWMS=JVU?C'VKO.HM/EUCR\U'[+^Q_B0\-<+>+P=3
M]G\YOZ[AF&$[<V2^V#<CNW3<K9NEMGC*)=OS:(ZHB8VNX7&WNHD^D''(TIP$
M\Q&G/=GWB6W^8%GXL:8]V[*,H=#MW)>S3AHFJ=35#Z[^(GP[M>;/A'/RKO5]
MW-XPMOA=MY>O/',Q+/-&_%U4ESRA)3Z7&<NDP']E=B\K+]HLA\86?WAK+]Z_
M%%>I-RRO)#'2V;3C&$RGL3Q[$+>#KW$1ART.2GP@\BW'&T\>Z2:DO.]^-C<(
M;!BQ\/;<**48_K2FN=R?_JHC2?RR[5>W/RKD?%;?[T<KSEYDORG?N\M/#M8S
M=BU8@NA+PW*5.+Y%P@CZE5I1]+B@(-[ZUW\XO\HT!UT H"W\DQ>S97 ]GWF.
M76T$KCR&B&Y<-XC3O8SVA*"1\I)!2H=(-7;5Z=F7-#_\F%G;?B[C9\'*C6/0
MUHT^M/H^LU>R[:3(,=[V7;4KOUJ1JHNQ6CZ_&;''65#25*4E(Z5M\P[0*E[&
M;;NZ3[LS0-Q\MYN#6[8K>QNM>TETU7Z#% .NOD)!Z>D=(.O00>GLK,Z*FO5J
M* 4 H!0"@% * 4 H!0"@% * 4!VL,O2GD1XS+LA]P\J&F4%QQ1\B4ZG3R] H
MVHZO@5A&=R7);BY3?!+6IDNS[;O/(#M[DKBZ@%,2(I"GT@\?IWE!;:%<>A(/
MGK"NYJ6EI576;!B[!.4>?+DX]452OK>OS"\[;O,MEZRR52M!JJ)+*$/*T_X3
MZ0EI9T'R5!)/;5+68FZ7%0IE;!*$7/$DY?Z7Q]3X?,C F?8'F&:6Z/C&,X]<
M;K>UWJ"5PFF2WZLTAN4'),U][DCPXK?,"IQQ03IT:ZC65Q,JQ8F[MR24%%^L
MTC?MHW3=,>.WX-BY/,\5-QI2BI+65=$ETMNAGO9SP76+&7X.1[G2V,FO+"FI
M4?&H04<;@R$$+1Z^\X$NWMQE8U*=$1]1Q"Q6#F[].ZG:Q%RVW]KI:]'4;/Y7
M^%F)@2AG;]*.1E*C5J/W47UR?_N-=6D4^LWHX   !( "0E*0E*0!H$I2D !*
M0- .H5KQUT4 H!0"@% 5'0?-\(H >D^<^_0%* 4 H!0%"0D$D@ =)/ "@/$]
M,TX-#7\,CA_LCKH"/4I2CJHDGM- <: M/(\+L62)*Y4?U:=IHBXQ0EN0#\WO
MA\B0@:]"AKV$5?M9%RUPUCU,C,W:<3.3<UR7NB4>/KZS"D_:S*(TP,0VH]PC
M+5Z$QN0TRA*=>!D-/+#C*@.)Y0L=AK.CF66JRT?4:M<\O[A"X[=I*=OH=4OE
M3=3(N/;7VJUH$J\*1=YP;4L-%*A;F5<I.B6E:+DE)ZW.'X-8US+G-\L-(U]9
M-X6P8^/'Q<I^+>I6GV4_1V$#H  E("4I "4I 2E(' !*1P2!V5[;J6*):+@*
MH!0"@% * 4 H!0"@.MUII]!;>;2ZV?FK&H\X/2#Y1QJJDX\#S.,;D>6XJQ+8
MFX\I(+D%16/_ ,=P@*'XCAX*\@.A\M94+VG>(F_MK7>L-M=3^HMM:'&U%#B%
M-K3P4A8*5 ^4&KR:?#@1;C*+Y9*C.-5*"@% * 4 H!0"@% 9\QW"<*SS;RT6
MC.L-Q3-K5'G7&5'MN78[:,DA1Y7KCH]9C1KS#FM1WR  5H"5$#0FL"[E96-D
MRN8MVY;FTDW&3BZ=3HU7T5-KQMCV7?=DM8N^8>+FXT9RDH7[5N[%2YGJE<C)
M)^E*IDDXOBYQY>('&<>_=)RWKM+F*BRVU.-.6M8*5VU=A3&%J-O6DZ*9[KNU
M:G4<:P_'O^-[QSS]XK7GJ^:O75ZU])./:]KEM[VF6-CO:G;=MV/#AX+@^,?#
MY>3E?3'EIZ#S3,*PNX6VPV:?AV*SK/BTF#,Q>U3,>M$FVXS,M;?=6V7CT%^&
MY&LLJW->BPY&2TIE/!) KU')R(3E=C<FKLTU)IOO)\5+K[&6KVR[-D6+&)D8
M>+<Q,649682M0<;,H*D)6HN+5N4?LN%*+A0]=PQO'+M=K-?KKC]CNE^QQ<IS
M';Y<;3;YUXL#DY"6YR[)<Y,=V;:ES6TA+I8<;+B1HK45YA>O6[<K5N<HVI^U
M%/2755=-/27[^W;=DY=G<,FQ9N9^.V[-R<(RG:<M).W-IR@Y+1\K55Q.-JQC
M&;%.O=TL>.6"RW/)IB;EDEQM%FMMLG9#<4A8%PODN%&8D7:< XKZ:0IQSTCQ
MXFER_>NQC"[.4X05(INO*NI=2/&+M>V8-V]D86-8LY&3/GO2MVXPE=DOM7'%
M)SEK[4JOTD3E.W&W6<RK;/S;;[!LRGV?A:9V5XEC^13;8 OO F!*N]OF/Q&T
MN>D$H4$\W'36KEC-S,6+AC7;MN$N*C)I/M29B;IY;\N[Y>MY&]8&%F9%KV)7
M[%J[*%'5<LIQDTD]:<*EP72RV6]VJ78;U9K3>+#/C"%.L5UML*X6:9"')I#E
M6J6R] D1$]VG1I390.4:#@*LPN7+4U=M2E&ZG5--II]:?%,D<K"P\[%G@YUJ
MU>P;D>65N<(SMRC^JX23BUHM*45-%HBWL6VWVYP:1+EX1M]@^&2K@PW%N$K$
M\2L&.29\9EPO-1YK]GM\-V4PTZ>9*%E20KB!K5Z_F9>4E')NW+D5P4I.5/E?
M'TD?M?ESR]L=R=W9<#"P[MR*C*5BQ;M.26J4G"*JD]4F^.IZ'\"P26K*%2\)
MP^4K.&V&LV5)QBR/JS)J*E*8K65J=A+.1-QD) ;$SO@@ <NFE467E14%&[<2
MM^QWGW*\>773U%R>Q;'<>2[F%B2>;3WBMFV_>.7V?'K%^+1<.?F2Z"X+?;[?
M:($*U6F!"M5KML9F%;K;;8K,&WP(4= ;CQ(4*,AN/%C1V@$H;;2E"4@  59G
M.5R3G-N4VZMO5M];9GX^/8P\>&)B0C:Q+45&$()1A"*T48Q22BEP2222T2.F
M[V>SY!:Y]DR"TVV^V6Z1U1+E9[S!BW2U7&*LI*XT^W3FGX<R.HI!*'$*22!P
MX56W<N6IJ[:E*%R/!IT:['T'C,P\/<,:>%N%JU?PKBY9V[D8SA./5*,DXR7H
M::/3!B0[9$A6^V1(UMM]NCL0[?!@1V8D.!#BMI:C1846.AIB+&C-("6VT)2A
M"0   !5)2E.;G-MR;JV^+?2R[9LVL:U#'QX1MX]N*C&,5RQC&*HE&*TBDM$E
MHEP+5&W&W0QZX8@-O\(&)7:<Y<[KBPQ.PC&[G<WI#4MZXW"QB![+FSWI;"'5
M/.M*<4XA*B>8 U?]\R_%61XMSWB*HI<SYDN%$ZU2IU$7_P#7?+ZV^YM,<'#6
MU79\\[/@6O"E-OF<Y6^7DE)R2;DXN3>M29O..8[D5F>QS(;!9+]CLAJ,P_8+
MU:8%ULC[,-;+L-EZTSH[\!UJ([';4TDMD-J0DIT*1I:MWKUF[XUJ4H7?UHMI
MU?%U3KKZ&9F9MVW;CAO;\_'LW\"2BG:N0C.W2-.5<DDXM*BHFJ)I46A%8KM]
M@&"&:<'P3#,+5<@P+DK$L7L>-FX"+WAC"?['@P_7/5^]5W?><W)S'334U<R,
MO+RJ>]7;EQ+AS2<J=G,VS$VO8-AV+G>QX.'ANY3G\"S;L\_+PYO#C'FI5TK6
ME72E3A(VZV\EQ<F@2L!PF5 S68W<LR@R<4L+\/+;DRM+K-QR>*[;UL7^>RZD
M*2]*2ZXE0!!!%569EJ4)J[<4[:I!\S[BZHZZ+K2*3\N^7KEG(Q[F!A2L9D^?
M(B[-MQOS3JI7ERTN23X2GS-$A/Q#$;HQ88UTQ3&[E'Q67#GXM'N-CM<YC&IU
MO:2Q;YN/LRHCJ+-,@L)"&78X;6T@!*2 -*\1R,B#F[=R<7<7>HVN:NK3ZTWQ
MJ9%_:-IRK=BUE8N/=MXLU*RIVX25F452,K:<6H2BDE&44G%:)H[U8WCB\B&8
M*QZQ*RX6PV5.5&T6\Y*FS%TOFT"^F/[4]E]^2OU?O>ZYCKRZUY\:]X7N_/+W
M>M>2KY:]=.%3V]MVZ6X_UB5BS_5O#\/Q^2/C>'6OA^)3GY*Z\G-RUUH5AXYC
MMNO%WR*W8_9(&09 B(W?[]"M,"+>[ZW;V^Y@-WFZL1VY]T1!9]%D/N+#2>"=
M!597[T[4;$YR=F%>6+;I&O&BX+U%;.W;=CYE[<,>Q9AN&13Q;L80C<NJ.D?$
MFDI3Y5I'F;HM$2SK;;S3K#S;;S#[3C+[+J$N-/LO(4VZRZVL%#C3K:BE22"%
M Z'A5M-IU6C1E3A"Y!V[B4H2333U33T::Z4UHUU$78<>Q_%;5%L.+V*S8U8X
M(<$&RX_:X-FM$(/.J?>$2VVYB-"C!U]Q2U<B$\RE$GB2:]W;MV_-W;\Y3NOC
M*3;;[6S&P<# VO%C@[98LXV#"O+;M0C;MQJZOEA!**J]71*KU)>K9EB@(-[Z
MUW\XO\HT!Y)$J-$;[V5(9C-ZZ!;[J&DDCI *R-3YJJDWHE5GB=RW;7-<E&*]
M+H>%F^662L-L76 XXHZ)0)" I1[$A1&I->O#FE5IT["U'+Q9ND+D&WZ25KP9
M!74]I^_0&.,MVPQS*N]DAKV3=E@Z7""A*0\OJ,V,.5J1J>E0Y7/PNJLJSF7;
M.C[T.ID'N6P8.X5FEX613VH]+_U1X-?.:Q93@&1XBM2I\7UFW\VC=UAA3L-0
MUX=\>7GBN'^:X$C7H)J7LY-J_P"RUS=3-#W#9\[;6W>CS6/UXZQ_R?H="RJO
MD4* 4 H!0"@% * 4 H!0%="> !)/  =)/4 .DD]5&Z*HUX)59?=BP*Y7/D?N
M!5;(:@%:+2#,=2>/T;"OJ@1UKT/D-8EW+A%4AK(F</9<C(2N7ZV[/IXOL_S,
MOVFQVRR-=U;XR&RH ./J].2\1UNO*])0\@T2.H5'W+T[OMO4V?%P\?#CRV(T
MZWTOUDPE*EJ"4)4M:CHE*02HD]0 XU;,I)MT7%EQ0[ M7*Y-46Q_P$$<Y'X:
M^(3YAJ:MN:I1$A9P6^]==%U(N^W@0#I$0AKT0DA*>"P--.\/2LCM/$5;;;>I
M(PA&VJ022+E8N#+O!P]TORGT#QZE$CE^[5#T>_L/:-1YJ 4 H!0"@% 5'0?-
M\(H >D^<^_0%* 4 H#RNRT-\$>FO_P H\YZZ C7'7'3JM6O8.A(\PH#KH!0"
M@% * HKY"_Q%_D&JKB4EP?880K,-8?$54"@% * 4 H!0"@% * 4!YI4.-,1R
MR&@H@:)<3Z+B/*E8X_!7N%R4.!9NV+5]4N)=O3\I:<ZQR(VJXY,ED<= /IT#
MI.J1KS@>3[U94+T9Z/29$7MNNVJSM]Z"^4@^T=G ^3S]E72/% * 4 H!0"@%
M ;1[9?P;;?S]Q_OKM1&7]^^Q?0;_ +%_:X=LOWF7]6,2PH!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0'3(D1XC#LJ6^S%C,(+CTB0ZAEAE &I6XZX4H0D#
MM-546VHI-MGF<X6X.Y<:C;7%MT2]9A^];C0OI!8.2>'25MSU@^J<JO22MA)"
M5R 0K4$Z)T[:R88TJ_Q51=1"Y&]VE'_PZ3;7M?9[5UF*YUPFW-\R)TAV2Z?G
M.*]%(X^BVV-$-HX]"0!64HQBJ15$:_=O7;\N>])RE]'8>.O1;+OLF9W6T!##
MBO7H(T'</J/>-)_Y#_%:-/YIU!JU<LPFM%1DEB;I?Q:0??M=3X^IF7+/D-JO
M:1ZH_P KX2%+AO:-R4:]B#P=3^$G72L*=J=OVN!L>-FV,I?PWWNI\?\ ,FZM
MF6<5H0XA;;J$.MN)4AQMQ(6VXA0T*%H4"E:3U@\#3APXE&HRBXR2<7QKT]IA
M7+=E[1=>]FXVXBRW \RC"6%*M4A9(^2D!3L)2CUHU1^"*S[&=.'=NZQ^<U7<
MO*V+D5O8'\*]^K]E_H]1K=?,<O>-R_4[U;WH3AYNZ<4.>-( /RHTE&K3R?,=
M1U@5*V[MNZJVW7ZC1LK#RL&YX67!PGT=*?8^#(2KAC"@% * 4 H!0#HXT#:2
MJ^!<MDQ.[WWE<::]5A$^E-D!26RG_D(TYWR1_-'+VD59N9%NUHWWC/Q-MR<U
M5BN6U^L^'JZS,EDQ&T64)<;:]:F@ F;)"5. Z#7N$?(8&HZ1Z7EJ,N9$[FCT
M1M6'MF+B+FBG.[^L_JZBZ/\ P_EPJPD^DD77H)B%99,KE6Z#'8/'F4/I%CAJ
M$(.A&O::\RFEP,JSB7+G>GI$NR)!BPDZ,-@'YSBM%.KU&G%1' >0<*MRDY/T
M$I:LV[2I!:]9ZZ\ET[&OEC^76* [* ]<>:]'T /.C^8OB/N'I% 3;$ME_@E7
M*OK0K@=?P3T*% >J@% * 4!4=!\WPB@!Z3YS[] 4H!0$?->TT:03U%9'7Q]$
M ]G;0$?0"@% * 4 H!0%%?(7^(O\DU5<2CX/L,(GI-9AK!2J@4 H!0"@% *
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%X10'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g284326tx_pg03b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284326tx_pg03b.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  Z L8# 1$  A$! Q$!_\0 S@ !  $$ P$!              4#! 8' 0((
M"0H! 0 " P$! 0             $!0$#!@('"!   0," 04)"0P' PP#
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M6UCTI<_Q*X_?JK[5-V.I#XM7WI;6/2ES_$KC]^JOM4W8ZD/BU?>EM8]*7/\
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MKFX>->I.?:WALT$!7#_X=1@/W9R ;@()R!>S1AD86L ( @" ( @" ( @" (
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M7NR\#1H]] 2,5FIF8&1SYCO'X#,G TEQQXT!+-:UC0UH#6M  :   !O (#E
M$ 0! $ 0! $ 0! $ 0$5<L\/$_WVH",0! $ 0%B_EN\8]XX(#J@"&5I-1W#S
M^N_QE3_O7J9'A78<S6_,S[7YEFO1X" AMHO4-W_P,_O!;*/S8]OL(?,/R-;_
M $V: 5L<,$ 0! $ 0! $ 0! $ 0! $ 0&P+/VE;2VF"GI'.I+A1TS&0Q0U<&
MC(V%C0UD;:F!T<F#&M !=I9%&G:4I-R6*DR\M/4',;2"I8QJ4HI)*2SP66&*
MP>W$F+U^8'9S9^WT];M-:+I1PRUL%)K[7JKDV-\L<SS(Z&1]).(P(LNCIG@*
MUPY76K2<:,HMI8YY$N[]=<OL*,:W,J56,'+=QAA-)X-YIM/#+HQ,AV=[9^R[
M:@1MM>V=G942X:-#=)C9JX$G --/<VTND_'<:7+35L+VA\RG+#6LUX%CR_UA
MZ:YFDK:\I*H_LS?PY;)[OAB;OL+FSTLCX'LG8^9I8^!S9F/!C&!:^,N:X'@*
MKJB:EGJ.LMI1G#>@TXOI3Q1DT=NK),NI<P;\F#.\[+WEK))>QV<YY9L/DQMQ
M_P!9Q_S("3IZ*"F)=&TZ9&&FYQ)PWL,C<O$@+I $!V;F?XH^FU =4 0! $ 0
M! $!I?M.[=-D>RZM@M-UI+O=;U4T;+A';K9#"QC*2626*&6HKZN6*GCUDD+L
M&M$CL!B0,F,ZUY?6NH[\'%03PQ?L1RW/O5W+?3]56UQ"K4NI04E&"6AMI-RD
MTEH>MGF+:'\W^UM67Q[,;,V2QQ$ ,J+G)47NM!W7:#3;Z)N(W"Q^&^K6GR:C
M'.K*4GU9+VLX*^_N7S*KC'E]"E2CKFW.7_+'P9HW:+MB[3MJ=-MWVTO75WC
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M>HPLXDEQ)<XYW$DN/&3B2I*262*K#/'I.$ 0! $ 0! $ 0! $ 0! $ 0! $
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M=TS2Z$6'#BO$JM.'$T2:-G=U\Z5.;6O#!;7D972]F]\F;I5$]!1?(?))4/\
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M-*NY1YKE.S9N4>3\G>X%-.9>DXZ-# Z- .C0#HT Z- .C0#HT Z- .C0#HT
MZ- .C0#HT!"[0>KCS'/1<OE9SS/R]_@Q6ZAQE?S+\MT<2[>XPCHU,*(=&@'1
MH"A4<Q-SG-N\T\YS?N/XF]PK*[N\\RT/3HZ-/=UGCWM.\YD]ON=/M3ZKW/-?
M[/ KNUT+Y?\ +I/G_.>-_FO^[PZ"IV7><M]O^7_^9]4<G_B>'?7F[T/Y7\VD
MSR3YB_-:?PN#O/7T'-1<OFV><<__ +;^+^DJ>7=W'?1T+3HZ?:>L^S_V.LOF
M_-3>;\CSJ?E_Q_*?+Q5)<_/EI/H?)?TVGP].C1I?CKZ\3,5H+4( @" ( @"
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g284326tx_pg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284326tx_pg04.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X00Q:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C4M8S R,2 W.2XQ-30Y,3$L(#(P,3,O,3 O,CDM
M,3$Z-#<Z,38@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z,T1%.3 P04,Y14,S,3%%-3@Q0S8Y.$%&.#,Q
M.3$X148B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,T1%.3 P04(Y14,S
M,3%%-3@Q0S8Y.$%&.#,Q.3$X148B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IA,&4Y8F9A-2TQ869A+31E8C8M861F8BTQ
M.&0V-S9F-V1F,F4B('-T4F5F.F1O8W5M96YT240](G5U:60Z.6)A8V4U-&(M
M-#4X92TT-6-D+6%C8F(M9#<Y839D93EB,#8T(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3YR<C$V-#0X,SPO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(#$U,3(Q,%].
M;W9O9V5N7T%P<&]I;G1S7T1R7T=A<FYE<E]!<U]#14\N9&]C>#PO<F1F.FQI
M/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \
M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  ^ L8# 1$  A$! Q$!_\0 R@ !  $% 0$! 0            4! P0&!P@"
M"0H! 0 " P$! 0             $!0$#!@('"!   0,#  8' 0D+"P('
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M+6X8)(9HS5CV'I'2"#H(.D'0=*@RBXO=EHT=):NV[UM7;34K<EHT9"P>P@"
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M<)(*F*9KM@>TM-.T;PJLC4CY<?=Q:3"]PVL >/FDE8!AD$&A!!'000>XH"B
M( @" ( @" ( @" ( @" (#U-Z:?P;C?IK_\ U<GFJC+_ %$O0=[P'^60ZY?B
MD;VHQ<&3%9W4WZN"0C:1N-_&?NM0$C%A)W?K98X^H5D/@ /% 2,6'M(R"\R3
M$4-'G=;HZ"UNDCW4!*-:UH#6@-:T4  H !T #4@*H @" ( @" ( @" ( @"
MC,EJA[7^\U 12 ( @" P7_'=_./OH#Y0!#*VG)<E_N%]_G+C^T<I<?"NHYF_
M^IG]Y^LP5[/ 0$1G_P#8\M_D)_R5LM?F1^\0\_\ 17O]MGGY6QPP0! $ 0!
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M?AD>7*5T'2#T*Y/FA^I'V!P!R!SZ  !_S.ST 4'^PVW0N0\Q_J+?W/\ ,S]
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M_24F1PWB&+^HLW(KGI5=JJN\URH-=.K7U=NQ;2%4( @" ( @" ( @" ( @"
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M4#W;R3R/ROZ=\O6G*_*&*BQ6(M'/DX;7/FN;JYEIQKV_NY2Z>\O)RT;SWG4
M  T #G<C(O95UWK\JS?9Z%R'U[A7".'\$PH\/X9;5O&CR;6V]LI-ZRD^5OT4
M6AMBTED$ 0! $!4:CV?=" '6>T^^@*( @+4DT<0&^=)U-&EQUZ:= T=* Q'7
MWR(_=<?N#S0&.ZZF=]]NC8T;OCK0%@N+M+B2=I)/OH"B ("H)&HD=B P)L9C
M+F43W&.L)YQ2DTUE;2RZ-7Z1\3G&G:O2G-*B;IUFF6/CSEOSMP<^=Q3?J,Q^
MB*1HT-$4@#0*- #'4 :*  +$?$NLVO2-%LH<14PYA[0L@( @" ( @" ( @"
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M+CX:$PF8@UK.XO%>CX(#6:.Q8<V^@D0Q+$.2KZ238QD3=V-C(VC[UC6L'<T
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32 4&T>/D@*@"ATC5U[1U(#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
